A Randomized Phase II Study Evaluating Pembrolizumab vs Topotecan in the Second-Line Treatment of Patients With Small Cell Lung Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Mar 2018
At a glance
- Drugs Pembrolizumab (Primary) ; Topotecan
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 20 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 27 Mar 2017 Status changed from not yet recruiting to recruiting.
- 17 Nov 2016 New trial record